Down 35%! This Just Shouldn't Happen

How does something like this happen?

Drugmakers talk to the Food and Drug Administration regularly about the design of their clinical trials. Roche has a ton of experience bringing new drugs to market. And yet, the drugmaker received a "refuse to file" letter from the FDA.

Having the FDA refuse to accept an application is about the worst thing that can happen to a drugmaker. It means the agency gave the application a onceover and decided it wasn't even worthy of a review. Drugmakers sometimes get sent back to the drawing board because of missing paperwork, but in this case the FDA refused to look at the application for Roche's trastuzumab-DM1 (T-DM1) because the agency says Roche didn't test the cancer drug in the right population of patients. Roche was seeking an accelerated approval, which requires less data, but can only be used for patients who don't have any other options; the FDA didn't think that was the case for the patients who went through Roche's phase 2 trial.

I don't know where the communication broke down. Did the FDA just spring this on Roche, or has the agency been saying this all along, and Roche just refused to listen to the advice? Either way, it shouldn't have happened.

The big loser in all this is Roche's partner, ImmunoGen (Nasdaq: IMGN  ) , which plummeted 35% today. The company developed the DM1 part of the T-DM1 and was set to get royalty and milestone payments after the approval. Instead it'll have to wait until the phase 3 trial testing T-DM1 against a combination of Roche's Xeloda and GlaxoSmithKline's (NYSE: GSK  ) Tykerb, which should be available in time for a mid-2012 filing.

While the delay in getting paid is disappointing, it's not disastrous for ImmunoGen. There's no reason to think the drug doesn't work, and the phase 3 trial needed to be completed in order for the drug to stay on the market after an accelerated approval anyway. Patient investors willing to wait for T-DM1 and for ImmunoGen's partnerships with sanofi-aventis (NYSE: SNY  ) , Biogen Idec (Nasdaq: BIIB  ) , and Biotest to pan out can grab ImmunoGen at discounted prices.

Run on over and check out Tim Hanson's pitch for Adidas.

GlaxoSmithKline is a Motley Fool Global Gains selection. Investing internationally doesn't have to be scary and it can certainly be profitable. Click here to grab a 30-day trial subscription to the newsletter where you'll see all of our current picks for a global economy.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool owns shares of Glaxo and has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (9)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 1283630, ~/Articles/ArticleHandler.aspx, 4/16/2014 12:46:13 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement